ArsenalBio and Genentech scaling up search for T cell levers 

ArsenalBio’s partnership with Genentech aims to accelerate understanding of what makes a good T cell therapy in order to guide both companies’ development of future candidates for solid tumors.

Arsenal Biosciences Inc. announced Tuesday a multiyear collaboration with the Genentech Inc. unit of  Roche (SIX:ROG; OTCQX:RHHBY) to identify features that enable T cell-based therapies to overcome immunosuppressive tumor microenvironments. Arsenal will receive $70 million in upfront payments plus research, development and commercial milestones...